Display options
Cite
Ortego-Jurado M, Callejas-Rubio JL, Ríos-Fernández R, et al. Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. J Osteoporos. 2015;2015:729451doi: 10.1155/2015/729451.
Ortego-Jurado, M., Callejas-Rubio, J. L., Ríos-Fernández, R., González-Moreno, J., González Ramírez, A. R., González-Gay, M. A., & Ortego-Centeno, N. (2015). Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. Journal of osteoporosis, 2015729451. https://doi.org/10.1155/2015/729451
Ortego-Jurado, Miguel, et al. "Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study." Journal of osteoporosis vol. 2015 (2015): 729451. doi: https://doi.org/10.1155/2015/729451
Ortego-Jurado M, Callejas-Rubio JL, Ríos-Fernández R, González-Moreno J, González Ramírez AR, González-Gay MA, Ortego-Centeno N. Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. J Osteoporos. 2015;2015:729451. doi: 10.1155/2015/729451. Epub 2015 Jun 01. PMID: 26124976; PMCID: PMC4466436.
Copy Download .nbib Format: NLM
Share it on

J Osteoporos. 2015;2015:729451. doi: 10.1155/2015/729451. Epub 2015 Jun 01.

Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study.

Journal of osteoporosis

Miguel Ortego-Jurado, José-Luis Callejas-Rubio, Raquel Ríos-Fernández, Juan González-Moreno, Amanda Rocío González Ramírez, Miguel A González-Gay, Norberto Ortego-Centeno

Affiliations

  1. Unidad de Medicina Familiar y Comunitaria, Hospital Son Llàtzer, Palma de Mallorca, Spain.
  2. Unidad de Enfermedades Autoinmunes, Hospital Clínico San Cecilio, Granada, Spain.
  3. Servicio de Medicina Interna, Hospital Son Llàtzer, Palma de Mallorca, Spain.
  4. Biomedical Research Institute, ibs. GRANADA, University Hospitals in Granada, University of Granada, Spain.
  5. Servicio de Reumatología, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain.

PMID: 26124976 PMCID: PMC4466436 DOI: 10.1155/2015/729451

Abstract

Glucocorticoids (GCs) are the cornerstone of the therapy in many autoimmune and inflammatory diseases. However, it is well known that their use is a double edged sword, as their beneficial effects are associated almost universally with unwanted effects, as, for example glucocorticoid-induced osteoporosis (GIO). Over the last years, several clinical practice guidelines emphasize the need of preventing bone mass loss and reduce the incidence of fractures associated with GC use. Calcium and vitamin D supplementation, as adjunctive therapy, are included in all the practice guidelines. However, no standard vitamin D dose has been established. Several studies with postmenopausal women show that maintaining the levels above 30-33 ng/mL help improve the response to bisphosphonates. It is unknown if the response is the same in GIO, but in the clinical practice the levels are maintained at around the same values. In this study we demonstrate that patients with autoimmune diseases, undergoing glucocorticoid therapy, often present suboptimal 25(OH)D levels. Patients with higher body mass index and those receiving higher doses of glucocorticoids are at increased risk of having lower levels of 25(OH)D. In these patients, calcidiol supplementations are more effective than cholecalciferol to reach adequate 25(OH)D levels.

References

  1. Nutr Rev. 2012 Mar;70(3):165-9 - PubMed
  2. Osteoporos Int. 2014 Aug;25(8):2157-8 - PubMed
  3. Med Clin (Barc). 2002 Jun 22;119(3):85-9 - PubMed
  4. Calcif Tissue Int. 2009 Nov;85(5):398-404 - PubMed
  5. J Bone Miner Res. 2012 Jan;27(1):160-9 - PubMed
  6. J Clin Endocrinol Metab. 2013 Aug;98(8):E1283-304 - PubMed
  7. Clin Endocrinol (Oxf). 1980 Mar;12(3):243-8 - PubMed
  8. J Clin Endocrinol Metab. 2011 Dec;96(12):3838-45 - PubMed
  9. Am J Clin Nutr. 2012 Jun;95(6):1350-6 - PubMed
  10. Ukr Biokhim Zh (1999). 2013 May-Jun;85(3):90-5 - PubMed
  11. J Cell Biochem. 2010 Aug 15;110(6):1314-23 - PubMed
  12. Endocrine. 2015 Sep;50(1):12-26 - PubMed
  13. J Clin Endocrinol Metab. 2012 Mar;97(3):738-44 - PubMed
  14. Transplant Proc. 1996 Dec;28(6):3485-7 - PubMed
  15. Curr Allergy Asthma Rep. 2011 Dec;11(6):526-38 - PubMed
  16. Lupus. 2011 Mar;20(3):330-1 - PubMed
  17. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515-26 - PubMed
  18. Lancet. 1974 Jul 20;2(7873):121-3 - PubMed
  19. Best Pract Res Clin Rheumatol. 2011 Dec;25(6):891-900 - PubMed
  20. Obes Rev. 2013 May;14(5):393-404 - PubMed
  21. BMC Musculoskelet Disord. 2007 Jan 10;8:3 - PubMed
  22. Bone. 2014 Feb;59:14-9 - PubMed
  23. J Lab Clin Med. 1977 Aug;90(2):399-404 - PubMed
  24. Osteoporos Int. 2012 Oct;23(10):2479-87 - PubMed
  25. Clin Exp Rheumatol. 2012 Nov-Dec;30(6):905-11 - PubMed
  26. N Engl J Med. 2011 Jul 7;365(1):62-70 - PubMed
  27. J Endocrinol. 2000 Mar;164(3):339-48 - PubMed
  28. Calcif Tissue Int. 1997 Feb;60(2):155-9 - PubMed
  29. Joint Bone Spine. 2014 Dec;81(6):493-501 - PubMed
  30. Curr Vasc Pharmacol. 2014 Mar;12(2):339-49 - PubMed
  31. Bone. 2012 Jul;51(1):54-8 - PubMed
  32. Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):681-91 - PubMed
  33. Endocrine. 2002 Mar;17 (2):109-18 - PubMed
  34. Rev Esp Salud Publica. 2012 Oct;86(5):461-82 - PubMed

Publication Types